Prescient Therapeutics (ASX:PTX) tables impressive results for December quarter
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary...
Biotechnology companies have emerged from the COVID pandemic in “healthy if not robust” shape and...
One of the leading clinical-stage oncology companies, Prescient Therapeutics Limited (ASX:PTX), has been making its...
Prescient Therapeutics Limited (ASX: PTX) has released the results for September quarter of fiscal year...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.